OR10K2

Across TCGA pan-cancer cohorts, OR10K2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR10K2 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher OR10K2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR10K2 expression acts as an unfavorable survival marker.

BLCA, HNSC, and CESC are the cancer types where OR10K2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.215	0.712	<.001	48	view →
HNSC	DFS	Median	IV	0.122	0.670	.008	19	view →
CESC	OS	Median	All	0.151	0.798	<.001	12	view →
STAD	DFS	Median	All	0.205	0.714	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	.003	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR10K2–BLCA (OS)

Open the BLCA breakdown →